Shares of ChemoCentryx Inc. (NASDAQ:CCXI) rose 1.5% during trading on Wednesday . The company traded as high as $4.80 and last traded at $4.68, with a volume of 59,099 shares traded. The stock had previously closed at $4.61.

CCXI has been the topic of a number of analyst reports. Zacks Investment Research raised ChemoCentryx from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research report on Wednesday, April 27th. JPMorgan Chase & Co. reissued a “buy” rating and issued a $11.00 price target on shares of ChemoCentryx in a research report on Tuesday, August 9th. Finally, Cowen and Company reissued a “hold” rating on shares of ChemoCentryx in a research report on Thursday, May 19th.

The firm’s market cap is $221.62 million. The stock’s 50-day moving average is $4.57 and its 200-day moving average is $3.82.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.